Analyst Price Target is $12.00
▲ +485.37% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Indaptus Therapeutics in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 485.37% upside from the last price of $2.05.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Indaptus Therapeutics. This Buy consensus rating has held steady for over two years.
Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.